Skip to Main Content

Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants

Conditions

Children's Health

Phase III

What is the purpose of this trial?

To show the superiority in safety of Smoflipid over IntralipidĀ® as measured by the number of study patients in each treatment group with conjugated bilirubin exceeding 2 mg/dL during the first 28 days of study treatment, confirmed by a second sample collected 7 days after the first sample.

  • Trial with
    Fresenius Kabi DEutschland GmbH
  • Start Date
    07/06/2017
  • End Date
    10/30/2017
Trial Image

For more information about this study, contact:

Christine Henry

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    02/22/2018
  • Study HIC
    #1510016597